Identification of RNA: 5-Methylcytosine Methyltransferases-Related Signature for Predicting Prognosis in Glioma

Abstract

Background: Glioma is the most common primary intracranial tumor, accounting for the vast majority of intracranial malignant tumors. Aberrant expression of RNA:5-methylcytosine(m 5 C) methyltransferases have recently been the focus of research relating to the occurrence and progression of tumors. However, the prognostic value of RNA:m 5 C methyltransferases in glioma remains unclear. This study investigated RNA: m 5 C methyltransferase expression and defined its clinicopathological signature and prognostic value in gliomas. Methods: We obtained the RNA-sequence and Clinicopathological data of RNA:m 5 C methyltransferases underlying gliomas from the Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) datasets. We analyzed the expression of RNA:m 5 C methyltransferase genes in gliomas with different clinicopathological characteristics and identified different subtypes using Consensus clustering analysis. Gene Ontology (GO) and Gene Set Enrichment Analysis (GSEA) was used to annotate the function of these genes. Univariate Cox regression and the least absolute shrinkage and selection operator (LASSO) Cox regression algorithm analyses were performed to construct the risk signature. Kaplan-Meier method and Receiver operating characteristic (ROC) curves were used to assess the overall survival of glioma patients. Additionally, Cox proportional regression model analysis was developed to address the connections between the risk scores and clinical factors. Results: We revealed the differential expression of RNA:m 5 C methyltransferase genes in gliomas with different clinicopathological features. Consensus clustering of RNA:m 5 C methyltransferases identified three clusters of gliomas with different prognostic and clinicopathological features. Meanwhile, functional annotations demonstrated that RNA:m 5 C methyltransferases were significantly associated with the malignant progression of gliomas. Thereafter, five RNA:m 5 C methyltransferase genes were screened to construct a risk signature that can be used to predict not only overall survival Wang et al. RNA:m 5 C Methyltransferases in Glioma but also clinicopathological features in gliomas. ROC curves revealed the significant prognostic ability of this signature. In addition, Multivariate Cox regression analyses indicated that the risk score was an independent prognostic factor for glioma outcome. Conclusion: We demonstrated the prognostic role of RNA:m 5 C methyltransferases in the initiation and progression of glioma. We have expanded on the understanding of the molecular mechanism involved, and provided a unique approach to predictive biomarkers and targeted therapy for gliomas.

M5C regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in lung adenocarcinoma

“…Studies have confirmed that m 5 C is involved in the progression of hepatocellular carcinoma (37,38). Also, there is increasing evidence that methylation regulatory factors can be used as prognostic and diagnostic markers of cancer (39)(40)(41)(42)(43). For example, the high expression of NSUN1 has been identified as a prognostic marker for non-small cell lung cancer (44)(45)(46).…”

Prognostic Value of an m5C RNA Methylation Regulator-Related Signature for Clear Cell Renal Cell Carcinoma

“…Increasing evidence suggests that dysregulated aberrant RNA epigenetic modifications may function as oncogenes or tumor suppressors in carcinogenesis and cancer progression. 25 , 26 Therefore, epigenetic regulators are promising diagnostic, prognostic, and predictive biomarkers for ccRCC. Some studies have focused on m 5 C DNA methylation genes in ccRCC that could serve as potential biomarkers for cancer diagnosis and prognosis.…”

m5C-Related Signatures for Predicting Prognosis in Cutaneous Melanoma with Machine Learning

“…Accumulating evidence indicated that m5C RNA methyltransferase-related regulators were implicated in tumorigenesis and tumor development in ovarian cancer, cervical cancer, prostate cancer, glioma, and other several tumors [ 12 , 40 ]. However, the current study did not investigate the relationship between m5C modifications and CM development.…”